in this issue
Pharma/Fine Chemicals Roundup – July 19
6:59 AM MDT | July 19, 2011 | By DEEPTI RAMESH
AJINOMOTO OMNICHEM AND GRANULES INDIA FORM PHARMA INTERMEDIATES AND API VENTURE IN INDIA
Ajinomoto (Tokyo) says its wholly owned subsidiary Ajinomoto OmniChem (Louvain-la-Neuve, Belgium) has signed an agreement with Granules India (Hyderabad, India), a manufacturer of active pharmaceutical ingredients (APIs) and pharmaceuticals, to form a 50-50 joint venture dubbed Granules OmniChem Pvt. Ltd. (Vishakhapatnam, India), to manufacture pharmaceutical intermediates and APIs. The new company will be established this month and begin construction of a plant in a special economic zone at Vishakhapatnam in November 2011, and production at the plant is expected to begin in January 2013. Capital investment in the jv, including future expenditures, is expected to total about $20 million to $25 million. Ajinomoto OmniChem manufactures and sells pharmaceutical intermediates and APIs. The establishment of the new company will increase OmniChem's cost competitiveness and production capacity. This will further enhance Ajinomoto's pharmaceutical intermediates business, Ajinomoto adds.
ORCHID ORDERED TO CLOSE API PLANT IN INDIA
Orchid Chemicals & Pharmaceuticals (Chennai, India) says its cephalosporin active pharmaceutical ingredient (API) manufacturing facility at Alathur, in the state of Tamil Nadu, India has received a closure notice from the Tamil Nadu pollution control board (TNPCB) citing non-compliance in the disposal of solid waste. Orchid says it is in discussions with TNPCB officials and is confident of resolving the issues and of resuming normal operations at the plant soon.
TEVA ACQUIRES THIRD LARGEST GENERICS FIRM IN JAPAN $934 MILLION
Teva Pharmaceutical Industries (Petah Tikva, Israel), a leading generics pharmaceutical company, says it has completed the acquisition of all of the shares in Taiyo Pharmaceutical Industry for $934 million. Taiyo is the third largest generics manufacturer in Japan with sales of about $530 million in 2010. Taiyo brings to Teva a portfolio of over 550 products and a strong presence in all major channels in the Japanese pharmaceutical market. Teva also gains access to Taiyo's R&D team, local regulatory expertise and a production facility. Following the acquisition, Teva expects to reach $1 billion in sales in Japan, ahead of its original 2015 target.
Japan is the second largest pharmaceutical market in the world, valued at $96 billion in 2010 with only a 23% rate of generic penetration, Teva says. The Japanese government has expressed its intention to increase generic penetration to 30% by the end of 2012, Teva says.
10 PHARMA COMPANIES NAMED IN HEPARIN CASE
US Government Officials have implored ten major pharmaceutical companies to give up information in the race to solve the 2007-2008 contaminated Chinese herparin incident.
The Committee on Energy and Commerce sent letters to Amphastar Pharmaceuticals, Momenta Pharmaceuticals, Siegfried USA, Sagent Pharmaceutical, APP Pharmaceuticals, Sanofi Aventis, Drug Source Company, Global Pharma Sourcing, Pacific Rainbow International, and Sandoz. The move comes after documents from the U.S. FDA indicated that the list of firms have information related to the case, in which 100 U.S. citizens died because of the adulteration of the popular blood-thinning drug’s supplies.
The letter, signed by committee chairman Fred Upton and members, states: “It is important to determine how the adulteration happened so that industry and government can take more effective proactive measures to reduce the risk of such adulteration in the future.”